Aromatasehemmer riskant für das Gehirn?

Zusammenfassung

Die Erfolge der endokrinen Therapiemöglichkeiten beim metastasierenden Brustkrebs sind beeindruckend. Die adjuvante endokrine Therapie befindet sich momentan im Wandel. Soll weiter wie seit 30 Jahren Tamoxifen eingesetzt werden oder Aromatasehemmer bis 5 oder mehr Jahre? Ehe eine großzügige Umstellung erfolgt, sind mögliche längerfristige Nachteile auf das ZNS zu klären. Das Enzym Aromatase sichert die elementare Östrogenversorgung der Neuronen in vielen Hirnregionen. Bei komplett inhibierter Östrogensynthese durch einen Aromatasehemmer lässt die Synapsenplastizität im Hippocampus nach. Neurobiologisch erklärbar ist das durch fehlende neuroprotektive Östrogeneffekte. Das kann neurodegenerative Veränderungen mit Lern- und Gedächtnisproblemen bewirken. Daher ist multizentrisch zu klären, ob längerfristig Aromatasehemmer für das Gehirn riskant sind. Bisher wurde kein deutlich längeres Überleben unter Aromatasehemmer gegenüber Tamoxifen nachgewiesen. Die Aromataseforschung weist auf mögliche Neurodegeneration hin - evtl. längerfristig bis zum Alzheimer-Risiko.

Abstract

Impressive successes have been achieved with the possibilities offered by the endocrinal treatment of metastasizing breast cancer. Adjuvant endocrinal therapy is presently undergoing a change. Should we continue to prescribe tamoxifen as we have been doing for the past 30 years, or should we resort to administering aromatase inhibitors for up to five or more years? Before initiating a large-scale change we should make every effort to find out whether there would be any long-term adverse effects on the central nervous system. The enzyme aromatase safeguards elementary oestrogen supply to the neurons in the brain region. If an aromatase inhibitor completely blocks oestrogen synthesis, there will be an decline of synapsis plasticity in the hippocampus. This can be explained neurologically by absence of neuroprotective effects exercised by the oestrogens and may trigger neurodegenerative changes associated with difficulties of learning and memory. Hence, it is mandatory to clarify multicentrically whether long-term administration of aromatase inhibitors involves brain risks. So far there has been no indication of a definitely longer survival due to administration of aromatase inhibitors than with tamoxifen. Aromatase research indicates possible neurodegeneration, possibly with long-term effects leading finally to Alzheimer's disease.

Tamoxifen - Aromatasehemmer - adjuvante Brustkrebstherapie - Neuroprotektion - Alzheimer-Risiko

Tamoxifen - aromatase inhibitor - adjuvant endocrinal therapy - neuroprotection - neurodegeneration - risk of Alzheimer's disease

Literatur

• 1 Azcoitia I. et al . Brain aromatase is neuroprotective.  Neurobiol. 2001;  47 318-329
• 2 Behl C. et al . Neuroprotective activities of estrogen: an update.  J Neurocytol. 2000;  29 351-358
• 3 Behl C. Sex hormones, neuroprotection and cognition.  Prog Brain Res. 2002;  138 135-142
• 4 Brake W G. et al . Novel target sites for estrogen action in dorsal hippocampus: an examination of synaptic proteins.  Endocrinology. 2001;  142 1284-1289
• 5 Coombes R C. et al . A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.  N Engl J Med. 2004;  350 1081-1092
• 6 Dubal D B. et al . Estradiol modulates bcl-2 in cerebral ischemia: a potential role for estrogen receptors.  J Neurosci. 1999;  19 6385-6393
• 7 Foidart A. et al . Pre- and post-translational regulation of aromatase by steroidal and non-steroidal aromatase inhibitors.  Brain Res. 1995;  701 267-278
• 8 Garcia-Segura L M. et al . Aromatase expression by astrocytes after brain injury: implications for local estrogen formation in brain repair.  Neuroscience. 1999;  89 567-578
• 9 Garcia-Segura L M. et al . Neuroprotection by estradiol.  Prog Neurobiol. 2001;  63 29-60
• 10 Geisler J. et al . Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a radomized cross-over study.  J Clin Oncol. 2002;  20 751-757
• 11 Genazzani A R. et al . Menopause and the central nervous system: intervention options.  Maturitas. 1999;  31 103-110
• 12 Goss P E. et al . A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.  N Engl J Med. 2002;  349 1793-1802
• 13 Gould E. et al . Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood.  J Neurosci. 1990;  10 1286-1291
• 14 Henderson V W. Estrogen, cognition, and women's risk of Alzheimer's disease.  Am J Med. 1997;  103 11-18
• 15 Höffken K. Aromatasehemmer der 3. Generation in der Therapie des Mammakarzinoms.  Onkologie. 1999;  5 58-67
• 16 Hojo Y. et al . Adult male rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017α and P450 aromatase localized in neurons.  Proc Natl Acad Sci USA. 2004;  101 865-870
• 17 Honjo H. et al . Estrogen as a growth factor to central nervous cells. Estrogen treatment promotes development of acetylcholinesterase-positive basal forebrain neurons transplanted in the anterior eye chamber.  J Steroid Biochem. 1992;  41 633-635
• 18 Hösli E. et al . Cellular localization of estrogen receptors on neurones in various regions of cultured rat CNS: coexistence with cholinergic and galanin receptors.  Int J Dev Neurosci. 1999;  17 317-330
• 19 Huober J. et al . Der Stellenwert von Aromatasehemmern der dritten Generation in der endokrinen Therapie des Mammakarzinoms - Zeit zum Umdenken?.  Geburtsh Frauenheilk. 2002;  62 15-21
• 20 Kretz O. et al . Hippocampal synapses depend on hippocampal estrogen synthesis.  J Neurosci. 2004;  24 5913-5921
• 21 Linford N. et al . The rapid effects of estrogen are implicated in estrogen-mediated neuroprotection.  J Neurocytol. 2000;  29 367-374
• 22 MacLusky N J. et al . Aromatase in the cerebral cortex hippocampus and mid-brain: ontogeny and developmental implications.  Mol Cell Neurosci. 1994;  5 691-698
• 23 McEwen B S. Estrogen action throughout the brain.  Recent Prog Horm Res. 2002;  57 357-384
• 24 Murphy D D. et al . Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones.  J Neurosci. 1996;  16 4059-4068
• 25 Naftolin F. et al . Aromatization of androstendione by the diencephalon.  J Clin Endocrinol Metab. 1971;  33 368-370
• 26 Peterson R S. et al . Rapid upregulation of aromatase mRNA and protein following neuronal injury in the zebra finch (Taeniopygia guttata).  J Neuroendocrinol. 2001;  13 317-323
• 27 Prange-Kiel J. et al . Para/autocrine regulation of estrogen receptors in hippocampal neurons.  Hippocampus. 2003;  13 226-234
• 28 Rapp R. et al . Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: A randomized trail.  JAMA. 2003;  289 2663-2672
• 29 Resnick S M. et al . Hormone therapy and risk of Alzheimer disease: a critical time.  JAMA. 2002;  288 2170-2172
• 30 Rune G M. et al . Estrogen up-regulates estrogen receptor alpha and synaptophysin in slice cultures of rat hippocampus.  Neuroscience. 2002;  113 167-175
• 31 Segal M. et al . Estradiol induces formation of dendritic spines in hippocampal neurons: functional correlates.  Horm Behav. 2001;  40 156-159
• 32 Sherwin B B. Cognitive assessment for postmenopausal women and general assessment of their mental health.  Psychopharmacol Bull. 1998;  34 323-326
• 33 Shughrue P J. et al . Estrogen is more than just a “sex hormone”: novel sites for estrogen action in the hippocampus and cerebral cortex.  Front Neuroendocrinol. 2000 b;  21 95-101
• 34 Veiga S. et al . Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase.  J Neurobiol. 2003;  56 398-406
• 35 Wehrenberg U. et al . Steroidogenic factor-1 expression in marmoset and rat hippocampus: co-localization with StAR and aromatase.  J Neurochem. 2001;  76 1879-1886
• 36 Yokomaku D. et al . Estrogen enhances depolarization-induced glutamate release through activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase in cultured hippocampal neurons.  Mol Endocrinol. 2003;  17 831-844